

Resource Summary Report

Generated by [NIF](#) on Aug 3, 2026

NSG-HLA-A2/HHD (NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(HLA-A/H2-D/B2M)1Dvs/SzJ)

RRID:BCBC_4611

Type: Organism

Proper Citation

RRID:BCBC_4611

Organism Information

URL:

Proper Citation: RRID:BCBC_4611

Description: NSG-HLA-A2/HHD mutant mice are immunodeficient and express human HLA class 1 heavy and light chains. This strain may be useful as a human hematopoietic engraftment host that supports the maturation of human T cells with transplantation <http://jaxmice.jax.org/strain/014570.html>.

Species: Mus musculus

Notes: NSG-HLA-A2/HHD mutant mice are immunodeficient and express human HLA class 1 heavy and light chains. This strain may be useful as a human hematopoietic engraftment host that supports the maturation of human T cells with transplantation <http://jaxmice.jax.org/strain/014570.html>.

Phenotype: Diabetes mellitus

Catalog Number: 4611

Database: BCBC, Beta Cell Biology Consortium

Database Abbreviation: BCBC

Organism Name: NSG-HLA-A2/HHD (NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(HLA-A/H2-D/B2M)1Dvs/SzJ)

Record Creation Time: 20230226T042341+0000

Record Last Update: 20260801T185750+0000

Ratings and Alerts

No rating or validation information has been found for NSG-HLA-A2/HHD (NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(HLA-A/H2-D/B2M)1Dvs/SzJ).

No alerts have been found for NSG-HLA-A2/HHD (NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(HLA-A/H2-D/B2M)1Dvs/SzJ).

Data and Source Information

Source: [Integrated Animals](#)

Source Database: BCBC, Beta Cell Biology Consortium

Usage and Citation Metrics

We found 1331 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Saini P, et al. (2026) Targeting Interactions Between Siglec-10 and $\alpha 5 \beta 1$ Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. *Cancer research*, 86(1), 99.

Bidkar AP, et al. (2025) Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted ^{225}Ac Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(14), 2963.

Tin E, et al. (2025) SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated Cytotoxicity. *Blood cancer discovery*, 6(3), 217.

Cook AL, et al. (2025) Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. *eLife*, 13.

You E, et al. (2025) LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma. *Cancer discovery*, 15(5), 1063.

Hoxhallari L, et al. (2025) Regulation of nucleotide excision repair by wild-type HRAS signaling in head and neck cancer. *Cancer gene therapy*, 32(6), 662.

Breunig M, et al. (2025) PPDPF is not a key regulator of human pancreas development. *PLoS genetics*, 21(4), e1011657.

Piraner DI, et al. (2025) Engineered receptors for soluble cellular communication and disease sensing. *Nature*, 638(8051), 805.

Ding L, et al. (2025) Granzyme B activated near-infrared-II ratiometric fluorescent nanoprobe for early detection of tumor response to immunotherapy. *Nature communications*, 16(1), 8054.

Gadiyar V, et al. (2025) Phospholipid scramblases TMEM16F and Xkr8 mediate distinct features of phosphatidylserine (PS) externalization and immune suppression to promote

tumor growth. *Cell death discovery*, 11(1), 506.

Sergeeva OA, et al. (2025) EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors. *Proceedings of the National Academy of Sciences of the United States of America*, 122(47), e2510829122.

Jawhar W, et al. (2025) Aberrant EZHIP expression drives tumorigenesis in osteosarcoma. *Nature communications*, 16(1), 6752.

Abhinav Ayyadevara VSS, et al. (2025) Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy. *bioRxiv : the preprint server for biology*.

Wang R, et al. (2025) MiR-181a-driven downregulation of cholesterol biosynthesis through SREBP2 inhibition suppresses uveal melanoma metastasis. *Journal of experimental & clinical cancer research : CR*, 44(1), 215.

Nargis N, et al. (2025) SOX2 Regulates Growth, Expression of Basal/Luminal Markers, and Chemotherapy Response in Urothelial Carcinoma. *Cells*, 14(13).

McDonald PC, et al. (2025) Neutrophil extracellular trap gene expression signatures identify prognostic and targetable signaling axes for inhibiting pancreatic tumour metastasis. *Communications biology*, 8(1), 1006.

Rincon-Torroella J, et al. (2025) ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1. *eLife*, 13.

Lane JI, et al. (2025) Intestinal lymphatic vasculature is functionally adapted to different drainage regions and is altered by helminth infection. *The Journal of experimental medicine*, 222(9).

Guo R, et al. (2025) Multiomic analysis reveals a key BCAT1 role in mTOR activation by B cell receptor and TLR9. *The Journal of clinical investigation*, 135(22).

Zeng Y, et al. (2025) Single-cell transcriptome analysis identifies MIF as a novel tumor-associated neutrophil marker for pancreatic ductal adenocarcinoma. *NPJ precision oncology*, 9(1), 293.